Monthly Archives: March 2005

Zometa (zoledronic acid) – FDA revise prescribing information

The FDA and Novartis have issued guidance to health care professionals about zoledronic acid. The advice applies to advanced cancer patients with a baseline creatinine clearance of 60 ml/min or lower. Novartis Letter [PDF] Revised drug label [PDF]

Posted in FDA | Comments Off